Galcanezumab

Patient with hypertension or its risk factors, CV disease, history of Raynaud's phenomenon. Pregnancy and lactation.

Significant: Serious hypersensitivity reactions (e.g. anaphylaxis, angioedema, dyspnoea, urticaria); new-onset or exacerbation of pre-existing hypertension; new-onset, recurrence or exacerbation of Raynaud's phenomenon; development of anti-galcanezumab antibodies.
Ear and labyrinth disorders: Vertigo.
Gastrointestinal disorders: Constipation.
General disorders and administration site conditions: Inj site reactions (e.g. pain, erythema, pruritus, bruising, swelling).
Skin and subcutaneous tissue disorders: Pruritus, rash.

This drug may cause vertigo, if affected, do not drive or operate machinery.

Evaluate the need for continued treatment regularly after therapy initiation. Monitor for signs and symptoms of hypersensitivity reactions, new-onset or worsening hypertension, and worsening or recurrence of pre-existing Raynaud's phenomenon.

Description:
Overview: Galcanezumab, a recombinant humanised IgG₄ monoclonal antibody, is a calcitonin gene-related peptide (CGRP) antagonist used as an antimigraine agent.
Mechanism of Action: Galcanezumab binds to the CGRP ligand and inhibits its binding with the CGRP receptor. CGRP, a potent vasodilator and pain-signalling neuropeptide, has been associated with migraine attacks.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 5 days.
Distribution: Volume of distribution: 7.3 L.
Metabolism: Degraded into small peptides and amino acids via catabolic pathways.
Excretion: Elimination half-life: 27 days.

Store between 2-8°C. Do not freeze or shake. Protect from light. If necessary, may be kept at room temperature (up to 30°C) for up to 7 days; do not store back in the refrigerator once taken out of refrigeration.

Antimigraine Preparations

N02CD02 - galcanezumab ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.

Brayfield A, Cadart C (eds). Galcanezumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/09/2025.

Eli Lilly and Company (NZ) Limited. Emgality 120 mg/mL Prefilled Pen or Prefilled Syringe data sheet 03 September 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 09/09/2025.

Emgality 120 mg Solution for Injection in Pre-filled Pen or Pre-filled Syringe (Eli Lilly Nederland B.V.). European Medicines Agency [online]. Accessed 09/09/2025.

Emgality Injection, Solution (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/09/2025.

Galcanezumab-gnlm. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 09/09/2025.

Galcanezumab. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 09/09/2025.

Joint Formulary Committee. Galcanezumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/09/2025.

Pontevia 120 mg Solution for Injection in Pre-filled Pen or Pre-filled Syringe (Zuellig Pharma Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 09/09/2025.